Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (674)	6/2/2003 2:26:32 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

IDM Obtains Its First Japanese Patent Monday June 2, 2:07 am ET [They have quite an extensive patent portfolio. If their IP is useful or not remains to be seen.] PARIS--(BUSINESS WIRE)--June 2, 2003--IDM (Immuno-Designed Molecules), a biopharmaceutical company specialized in cellular immunotherapy, has been issued its first Japanese patent (Japan No. 541 583). This patent, called "New antigen presenting cells, a process for preparing the same and their use as cellular vaccines" covers the preparation and use of Dendritophages® for therapeutic anti-cancer vaccination. Dendritophages are one of the two families of immune therapy products called Cell Drugs developed by IDM against cancer. Dendritophages are experimental therapeutic vaccines, produced from dendritic cells loaded with tumor antigens. Studies are in progress to assess their ability to prevent the recurrence of certain cancers. The IDM product portfolio includes Phase II therapeutic vaccines for prostate cancer and melanoma. IDM was already issued this patent in Australia. It is pending in Canada and in Europe and will probably be authorized soon in the USA. The IDM portfolio includes 78 issued patents (including 18 in the United States) and 91 pending patent applications (including 22 in the United States). Jean-Loup Romet-Lemonne, President and CEO of IDM notes: "Given the length of the procedures at the Japanese patent office, we are especially pleased to obtain this first patent. It will reinforce the attraction of IDM for partnerships with Japanese companies." IDM - The Immunogenics Company® IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.